

ASX Announcement

HER-Vaxx HERIZON study results to be featured at ESMO Asia Congress 2022

Sydney, Australia, 7 October 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce that an abstract regarding the overall survival results from its HER-Vaxx HERIZON study has been accepted for an oral presentation at the ESMO Asia Congress 2022, being held in Singapore 2-4 December 2022.

The annual event brings together cancer professionals from Asia as well as other regions globally to present and discuss the latest scientific and clinical advances from across the field of oncology, of relevance at both a global level and within Asia-Pacific.

The oral presentation and abstract, number 74MO, is titled 'HERIZON Overall Survival Results: A study of IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2 Overexpressing Metastatic or Advanced Gastric/GEJ Cancer'. It will be presented as part of a session on gastrointestinal tumours by principal investigator Marina Maglakelidze at 1:40pm (SGT) on 4 December 2022.

The HERIZON study was a Phase 2 clinical trial of Imugene's HER-Vaxx technology in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.

The data and information presented as part of ESMO will be announced following the lifting of the embargo in late November 2022.

For more about ESMO Asia Congress 2022, please visit: <https://www.esmo.org/meetings/esmo-asia-congress-2022>

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
investor@imugene.com



Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

View us on YouTube @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia